...
BCYCMICRO

Bicycle Therapeutics plc

HealthcareBiotechnology
$5.73
$0.00(+1.60%)
52W$5.18
$11.16
FinancialsValuationvs REGN
Updated Mar 1, 12:00 AM
RSI44
RS Rating23/99
Beta1.17
Volatility62%
F-Score5/9
Mkt Cap$111M
DOWNTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

DOWNTREND

Bicycle Therapeutics plc is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 23), showing significant lag compared to the market leaders. Earnings contraction of 15% provides fundamental context to the price action. Investors should exercise caution due to high volatility (62% annualized), which requires wider risk management.

Relative Strength
23
out of 99
Lagging
Trend Score
0/4
Minervini Criteria
DOWNTREND
Risk (Beta)
1.17
vs S&P 500
ABOVE MKT
52W Position
9%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

DOWNTREND0/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$6.33
50 SMA > 100 SMA$6.86
100 SMA > 150 SMA$7.06
150 SMA > 200 SMA$7.30

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$5.64+1.57%ABOVE
50 SMA$6.33-9.49%BELOW
100 SMA$6.86-16.42%BELOW
150 SMA$7.06-18.82%BELOW
200 SMA$7.30-21.50%BELOW

Price Performance

1D+1.6%
1W+5.3%
1M-12.9%
3M-23.4%
6M-19.1%
YTD-14.2%
1Y-47.8%
3Y-36.8%
52-Week Trading Range9% from low
$5.73
52W Low$5.18
52W High$11.16

Technical Indicators

RSI (14)NEUTRAL
44.1
305070
VCP ScoreCOOL
4/10
Base depth: 43.1%

Risk Profile

Beta
1.17
52W Vol
62%
ATR
$0.30
Max DD (1Y)
-52%

Volume Analysis

Today
5
50D Avg
264.4K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+36%
$-0.74
Q1'25-42%
$-0.88
Q2'25-48%
$-1.14
Q3'25-15%
$-0.85
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+20.65%
3 Years:+44.48%
TTM:-23.20%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-9.73%

Stock Price CAGR

10 Years:-7.13%
5 Years:-25.91%
3 Years:-36.83%
1 Year:-47.77%

Return on Equity

10Y Avg:-90.9%
5Y Avg:-41.2%
3Y Avg:-40.6%
Last Year:-40.5%

Key Metrics

Market Cap$111M
Gross Margin-3.9%
Net Margin-4.8%
Piotroski F-Score5/9

More BCYC Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

BCYC vs REGNREGNCNTAIMNMCLDX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 23 meansBCYC outperformed 23% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.17 means 17% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is BCYC in an uptrend right now?

BCYC has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.

Is BCYC overbought or oversold?

BCYC's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.

Is BCYC outperforming the market?

BCYC has a Relative Strength (RS) Rating of 23 out of 99. BCYC is currently lagging the broader market.

Where is BCYC in its 52-week range?

BCYC is trading at $5.73, which is 51% of its 52-week high ($11.16) and 9% above its 52-week low ($5.18).

How volatile is BCYC?

BCYC has a Beta of 1.17 and 52-week volatility of 62%. It's more volatile than the S&P 500 - expect bigger swings.